Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03880656 · ClinicalTrials.gov registry record · Phase 1
BM-MNCs for Lower Extremity Compartment Syndrome Injury
A Phase 1 study of Compartment Syndrome Traumatic Lower Extremity, sponsored by Oregon Health and Science University.
- Active
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT03880656: Active Phase 1 study of Compartment Syndrome Traumatic Lower Extremity, sponsored by Oregon Health and Science University.
NCT03880656 is a Phase 1 study of Compartment Syndrome Traumatic Lower Extremity that is active but no longer recruiting, run by Oregon Health and Science University. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03880656, a Phase 1 study of Compartment Syndrome Traumatic Lower Extremity, is active but no longer recruiting, sponsored by Oregon Health and Science University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 1 study to assess safety and tolerability of intramuscular administration of two different doses of autologous bone marrow mononuclear cells (BM-MNCs) for treatment of lower extremity injury complicated by compartment syndrome injury.
Primary Outcome
Local and systemic reactions, serious adverse events and unexpected serious adverse events.
Conditions Studied
Interventions
- BIOLOGICAL Intramuscular administration of autologous BM-MNCs
Study Locations (1)
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-12-04 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
What the registry record for NCT03880656 still lists
NCT03880656 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Compartment Syndrome Traumatic Lower Extremity appearing as the primary indexed condition, and to 1 intervention - of which Intramuscular administration of autologous BM-MNCs is the first listed.
NCT03880656 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT03880656 about?
NCT03880656 is a clinical study titled "BM-MNCs for Lower Extremity Compartment Syndrome Injury". This is a phase 1 study to assess safety and tolerability of intramuscular administration of two different doses of autologous bone marrow mononuclear cells (BM-MNCs) for treatment of lower extremity injury complicated by compartment syndrome injury.
What is the current status of trial NCT03880656?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2019-12-04. Estimated completion is 2026-06.
What conditions does trial NCT03880656 study?
This clinical trial studies the following conditions: Compartment Syndrome Traumatic Lower Extremity.
What interventions are being tested in trial NCT03880656?
The interventions under investigation include: Intramuscular administration of autologous BM-MNCs (BIOLOGICAL).
Who is sponsoring clinical trial NCT03880656?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03880656 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03880656's enrollment target sits among peer trials
18 1720th of 2000 higher than 216 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI